Evidence map›Paper›PMID 41193854›Full record

ArticleBritish journal of cancer2026

Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.

Noor A Lokman, Anne M Macpherson, Annaliese R Thompson, Zoe K Price, Lizamarie Goonetilleke, Mark R Condina, Clifford Young, Peter Hoffmann, Martin K Oehler, Carmela Ricciardelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Microorganisms · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noor A Lokman *Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia. noor.lokman@adelaide.edu.au.
Anne M Macpherson *Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Annaliese R Thompson *Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Zoe K PriceDiscipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Lizamarie GoonetillekeDiscipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Mark R CondinaMass Dynamics Pty Ltd, Melbourne, VIC, Australia.
Clifford YoungMass Spectrometry and Proteomics Group, Clinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA, Australia.
Peter HoffmannMass Spectrometry and Proteomics Group, Clinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA, Australia.
Martin K OehlerDiscipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Carmela RicciardelliDiscipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia. carmela.ricciardelli@adelaide.edu.au.ORCID http://orcid.org/0000-0001-7415-1854

Funding

Ovarian Cancer Research Foundation (OCRF) N/A
6 · The paper itself

Abstract

backgroundThis study characterised the proteins from EVs in the serum from high-grade serous ovarian cancer (HGSOC) compared to healthy controls.

methodsSerum EVs were isolated, followed by label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify differentially expressed proteins. We validated the expression of 4 EV proteins increased in cancer serum (KRT4, MARCKS, SPP1/OPN, and UCHL1) in HGSOC tissues and normal ovarian tissues using online databases and independent HGSOC patient tissue cohorts. We additionally investigated the effects of the UCHL1 inhibitor, LDN-57444, on HGSOC cell metabolic activity, motility, invasion, and apoptosis in HGSOC tissues using patient-derived explant assays.

resultsProteomics analysis identified 28 EV proteins that were upregulated in HGSOC compared to healthy controls. We confirmed that UCHL1 protein levels were increased in HGSOC tissues compared to normal (OSE and FT) and benign epithelium. High stromal UCHL1 levels were associated with reduced progression-free survival in HGSOC. The UCHL1 inhibitor, LDN-57444, reduced the cell metabolic activity of ovarian cancer cell lines and primary ovarian cancer cells with high UCHL1 levels. LDN-57444 blocked the motility and invasion of OVCAR3 cells and promoted apoptosis in the HGSOC patient explant tissue assay.

conclusionUCHL1 has the potential to be used as a novel prognostic and therapeutic target for HGSOC.

Indexed as

Biomarkers, TumorCystadenocarcinoma, SerousExtracellular VesiclesOvarian NeoplasmsUbiquitin ThiolesteraseApoptosisCell Line, TumorCell MovementFemaleHumansIndolesMiddle AgedNeoplasm GradingOximesProteomicsBiomarkers, TumorIndolesLDN 57444OximesUbiquitin ThiolesteraseUCHL1 protein, human

Identifiers

PMID41193854
PMCPMC12819396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.